Kodiak Sciences (KOD) Operating Income (2017 - 2026)
Kodiak Sciences' (KOD) quarterly Operating Income came in at -$59.8 million in Q1 2026, down 1.19% YoY from -$60.5 million in Q1 2025, and down 4.05% on a QoQ basis from -$57.5 million in Q4 2025.
Kodiak Sciences (KOD) Operating Income (2017 - 2026) Analysis & Trends
Kodiak Sciences (KOD) has 10 years of Operating Income data on file, last reported at -$59.8 million in Q1 2026.
- Quarterly Operating Income fell 1.19% year-over-year to -$59.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$235.1 million (down 17.62% YoY) and the FY2025 annual result came in at -$234.4 million, down 25.44% from the prior year.
- Operating Income slipped to -$59.8 million in Q1 2026, from -$57.5 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$46.1 million in Q1 2024 to a low of -$95.8 million in Q1 2022.
- A 5-year average of -$64.7 million and a median of -$59.8 million in 2026 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2022 — Operating Income tumbled 89.42% — and 2024, when it surged 43.44%.
- Tracing KOD's Operating Income over 5 years: stood at -$74.1 million in 2022, then gained by 14.44% to -$63.4 million in 2023, then gained by 27.13% to -$46.2 million in 2024, then decreased by 24.41% to -$57.5 million in 2025, then decreased by 4.05% to -$59.8 million in 2026.
- The last three Operating Income figures came in at -$59.8 million (Q1 2026), -$57.5 million (Q4 2025), and -$62.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Kodiak Sciences | 2.60 Bn | 2.60 Bn | - | -66.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -66.84 Mn |
| Mar 31, 2026 | -59.78 Mn |
| Dec 31, 2025 | -57.45 Mn |
| Sep 30, 2025 | -62.35 Mn |
| Jun 30, 2025 | -55.51 Mn |
| Mar 31, 2025 | -59.07 Mn |
| Dec 31, 2024 | -46.18 Mn |
| Sep 30, 2024 | -46.63 Mn |
| Jun 30, 2024 | -47.98 Mn |
| Mar 31, 2024 | -46.06 Mn |
| Dec 31, 2023 | -63.37 Mn |
| Sep 30, 2023 | -54.50 Mn |
| Jun 30, 2023 | -84.83 Mn |
| Mar 31, 2023 | -74.62 Mn |
| Dec 31, 2022 | -74.07 Mn |
| Sep 30, 2022 | -79.48 Mn |
| Jun 30, 2022 | -92.07 Mn |
| Mar 31, 2022 | -95.77 Mn |
| Dec 31, 2021 | -93.05 Mn |
| Sep 30, 2021 | -67.54 Mn |